Connor, Clark & Lunn Investment Management (CC&L)
SYRS

Connor, Clark & Lunn Investment Management (CC&L)’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio SYRS Stock Details SYRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-1,647
Closed -$16K – 1269
2022
Q2 		$16K Sell
1,647
-12,069
-88% -$113K ﹤0.01% 1017
2022
Q1 		$163K Buy
13,716
+1,853
+16% +$33.1K ﹤0.01% 958
2021
Q4 		$387K Buy
11,863
+1,532
+15% +$62K ﹤0.01% 850
2021
Q3 		$462K Buy
10,331
+2,726
+36% +$133K ﹤0.01% 786
2021
Q2 		$414K Buy
+7,605
New +$450K ﹤0.01% 820
2019
Q3 		– Sell
-2,884
Closed -$267K – 1108
2019
Q2 		$267K Sell
2,884
-9,002
-76% -$627K ﹤0.01% 849
2019
Q1 		$1.09M Sell
11,886
-370
-3% -$25.8K 0.01% 514
2018
Q4 		$683K Buy
12,256
+390
+3% +$29.6K ﹤0.01% 638
2018
Q3 		$1.41M Buy
11,866
+1,600
+16% +$186K 0.01% 507
2018
Q2 		$1.05M Buy
10,266
+4,535
+79% +$562K 0.01% 603
2018
Q1 		$744K Buy
5,731
+4,270
+292% +$467K ﹤0.01% 519
2017
Q4 		$142K Buy
+1,461
New +$196K ﹤0.01% 741

Other funds holding SYRS

AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
ABG
Ally Bridge Group New York $124M AUM 249.88% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s SYRS Position: Q3 2022 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q3 2022, closing a stake of 1,647 shares — an estimated $16K sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in SYRS in Q4 2017 and held it in 12 quarters. The position peaked at $1.41M in Q3 2018. 53 funds tracked by Wall St. Rank hold SYRS as of Q3 2022.

  • Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • Connor, Clark & Lunn Investment Management (CC&L) sold 1,647 Syros Pharmaceuticals, Inc. Common Stock shares in Q3 2022, an estimated $16K.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q4 2017 and held it in 12 quarters.
  • Connor, Clark & Lunn Investment Management (CC&L)'s Syros Pharmaceuticals, Inc. Common Stock position peaked at $1.41M in Q3 2018.
  • 53 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q3 2022.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q3 2022, filed 10 Nov 2022.